Tenax Therapeutics (TENX)
NASDAQ:TENX
Want to see TENX full AI Analyst Report?
Top Page
Tenax Therapeutics
(NASDAQ:TENX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$13.50
▼(-6.57% Downside)
Action:ReiteratedDate:04/22/26
The score is held down primarily by weak financial performance (no revenue, expanding losses, and accelerating cash burn) and limited valuation support (negative P/E and no dividend). Technicals are mixed/neutral, while the CFO appointment is a modest positive but not enough to offset the funding and loss profile.
Positive Factors
Low leverage / strengthened balance sheet
Reported total debt of $0 and a meaningful rise in equity (from ~$8.1M to ~$97.1M) materially reduce refinancing and interest burden. This stronger capital base increases runway for registrational trials, preserves strategic optionality, and lowers near-term liquidity stress while programs advance.
Negative Factors
Pre-revenue with widening net losses
Tenax’s persistent pre-revenue status and a jump in net loss to roughly $52.6M in 2025 from ~$17.6M the prior year indicate structural profitability challenges. Large, sustained losses erode equity, force external financing, and increase execution risk absent clinical success or strategic partnering.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strengthened balance sheet
Reported total debt of $0 and a meaningful rise in equity (from ~$8.1M to ~$97.1M) materially reduce refinancing and interest burden. This stronger capital base increases runway for registrational trials, preserves strategic optionality, and lowers near-term liquidity stress while programs advance.
Read all positive factors
Tenax Therapeutics (TENX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$229.07M
Dividend YieldN/A
Average Volume (3M)510.83K
Price to Earnings (P/E)―
Beta (1Y)0.47
Revenue GrowthN/A
EPS Growth74.82%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.34
Shares Outstanding17,197,613
10 Day Avg. Volume577,990
30 Day Avg. Volume510,831
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)4.92
Price to Sales (P/S)0.00
P/FCF Ratio-13.35
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$31.50Price Target Upside117.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.56
Revenue Forecast (FY)N/A
Tenax Therapeutics Business Overview & Revenue Model
Company Description
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan...
How the Company Makes Money
Tenax Therapeutics’ revenue model is primarily tied to the development and potential commercialization of its drug candidates. In periods before product approval and launch, the company generally does not generate meaningful recurring revenue from...
Tenax Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
62
Positive
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -56.38M | -17.58M | -7.68M | -10.93M | -32.36M |
| Net Income | -52.60M | -17.60M | -7.71M | -11.05M | -32.47M |
Balance Sheet | |||||
| Total Assets | 104.23M | 96.69M | 11.68M | 3.40M | 5.99M |
| Cash, Cash Equivalents and Short-Term Investments | 97.56M | 94.85M | 9.79M | 2.12M | 5.58M |
| Total Debt | 0.00 | 0.00 | 500.90K | 807.89K | 290.78K |
| Total Liabilities | 7.16M | 4.69M | 3.59M | 1.91M | 1.75M |
| Stockholders Equity | 97.07M | 91.99M | 8.10M | 1.49M | 4.24M |
Cash Flow | |||||
| Free Cash Flow | -35.80M | -14.81M | -5.90M | -12.02M | -10.86M |
| Operating Cash Flow | -35.80M | -14.81M | -5.90M | -12.01M | -10.86M |
| Investing Cash Flow | 0.00 | 0.00 | 3.00K | -2.32K | 452.61K |
| Financing Cash Flow | 38.51M | 99.87M | 13.57M | 8.55M | 9.74M |
Tenax Therapeutics Technical Analysis
Positive
14.45
Price Trends
13.52
Positive
12.89
Positive
9.72
Positive
Market Momentum
0.15
Positive
51.21
Neutral
22.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TENX, the sentiment is Positive. The current price of 14.45 is below the 20-day moving average (MA) of 14.59, above the 50-day MA of 13.52, and above the 200-day MA of 9.72, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 51.21 is Neutral, neither overbought nor oversold. The STOCH value of 22.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TENX.
Tenax Therapeutics Risk Analysis
Tenax Therapeutics disclosed 37 risk factors in its most recent earnings report. Tenax Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tenax Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $777.22M | -4.15 | -170.83% | ― | ― | 44.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $20.08M | -0.53 | -119.92% | ― | -49.87% | 67.92% | |
48 Neutral | $30.27M | -0.74 | -309.60% | ― | ― | 65.02% | |
48 Neutral | $21.86M | -1.28 | -74.15% | ― | 13.77% | 30.30% | |
47 Neutral | $229.07M | -7.69 | -51.83% | ― | ― | 74.82% | |
41 Neutral | $2.31M | -0.52 | ― | ― | ― | 84.28% |
* Healthcare Sector Average
TENX
Tenax Therapeutics
13.32
7.96
148.51%
TPST
Tempest Therapeutics
2.11
-4.56
-68.37%
RLMD
Relmada Therapeutics
7.41
7.05
1975.63%
VYNE
VYNE Therapeutics
0.66
-0.69
-51.41%
LGVN
Longeveron
0.86
-0.60
-40.96%
CLDI
Calidi Biotherapeutics
0.21
-5.01
-95.94%
Tenax Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Tenax Therapeutics Names New CFO to Support Growth
Positive
Apr 22, 2026
On April 22, 2026, Tenax Therapeutics appointed veteran healthcare finance executive Thomas R. Staab, II as chief financial officer, effective May 11, 2026, succeeding interim CFO Thomas A. McGauley, who will remain in a consulting role through th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.